Table 2.
HRs reflecting of primary, sensitivity, and subgroup comparative analyses of PFS
| Direct within-study treatment comparisons | ITCs | ||
|---|---|---|---|
| MAIA D-Rd vs MAIA Rd | SWOG S0777 VRd vs SWOG S0777 Rd | MAIA D-Rd vs SWOG S0777 VRd | |
| Primary analysis: adjusted (aligned I/E criteria and propensity-score weighted) | 0.52 (0.41–0.67); P < 0.0001 | 0.88 (0.63–1.23); P = 0.46 | 0.59 (0.39–0.90); P = 0.01 |
| Sensitivity analyses | |||
| Aligned I/E criteria but no propensity-score weighting | 0.54 (0.45–0.66); P < 0.0001 | 0.84 (0.60–1.17); P = 0.31 | 0.65 (0.44–0.95); P = 0.03 |
| Doubly robust analysis | 0.51 (0.40–0.65); P < 0.0001 | 0.89 (0.63–1.25); P = 0.50 | 0.57 (0.38–0.87); P = 0.01 |
| Restricted to patients with hemoglobin > 9 g/dL | 0.51 (0.39–0.66); P < 0.0001 | 0.91 (0.64–1.30); P = 0.61 | 0.56 (0.36–0.86); P = 0.01 |
| Subgroup analysis | |||
| High cytogenetic riska | 0.58 (0.35–0.94); P = 0.03 | 1.02 (0.30–3.20); P = 0.97 | 0.57 (0.16–1.98); P = 0.37 |
Data reported as HR (95% CI)
HR hazard ratio, PFS progression-free survival, ITCs indirect treatment comparisons, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, SWOG Southwest Oncology Group, VRd bortezomib plus lenalidomide/dexamethasone, I/E inclusion/exclusion, CI confidence interval
aHigh cytogenetic risk was defined in the MAIA and SWOG S0777 trials as the presence of ≥ 1 high-risk cytogenetic abnormality (del17p, t[14;16], or t[4;14]). Note that the high cytogenetic risk subgroup analysis was based on small sample sizes (MAIA, n = 91; SWOG S0777, n = 17)